TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19032566
Drug: Colloid boluses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid boluses of 200 ml until stroke volume did not increase >or=10%
Study: 15016643
Drug: CHOP‐21 (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP‐21 (standard chemotherapy every 3 weeks)
Study: 15016643
Drug: CHOEP‐21 (CHOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOEP‐21 (CHOP plus etoposide 100 mg/m2 days 1‐3)
Study: 15016643
Drug: CHOP‐14 (biweekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP‐14 (biweekly chemotherapy)
Study: 11757689
Drug: Triple eradication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple eradication therapy (Clarithromycin 500 mg/d, Metronidazol 800 mg/d, Omeprazol 40 mg/d for 7 days)
Study: 29185480
Drug: JNJ‐39393406 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐39393406 (100 mg b.i.d.)
Study: 24423155
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day TTP488
Study: 24423155
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day TTP488
Study: 24423155
Drug: TTP488 plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTP488 plasma concentrations (7.6-16.8 ng/mL)
Study: 24423155
Drug: TTP488 plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTP488 plasma concentrations (46.8-167.0 ng/mL)
Study: 22188544
Drug: Clopidogrel hydrogen
Normalized name: Clopidogrel hydrogen sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel hydrogen sulfate (CHS) 600 mg loading dose followed by 75 mg/day
Study: 22188544
Drug: Clopidogrel besylate
Normalized name: Clopidogrel besylate
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel besylate (CB) 600 mg loading dose followed by 75 mg/day
Study: 17485382
Drug: Post transplant
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post transplant maintenance and targeted conditioning therapies such as bone seeking radioisotopes.
Study: 10560446
Drug: Belief in
Normalized name: Ora Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belief in clinical trials increasing knowledge about treatment options
Study: 10560446
Drug: Desire for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desire for optimum treatment for patients
Study: 3552010
Drug: Diazemuls (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazemuls (0.15 mg kg‐1)
Study: 6136290
Drug: Midazolam (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.07 mg kg‐1)
Study: 31646475
Drug: Nebulized dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nebulized dexamethasone 8 mg 1 hour before surgery
Study: 16800343
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy using Cisplatin and Etoposide along with Wobe Mugos E
Study: 16800343
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy using Cisplatin and Etoposide
Study: 10925060
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of two sympathetic tests
Study: 10925060
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all five tests
Study: 6105118
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g daily sulphasalazine
Study: 6105118
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g daily sulphasalazine
Study: 6105118
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g daily sulphasalazine
Study: 30008106
Drug: High-protein nutrient
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein nutrient preload (50-g Parmesan cheese, one boiled egg, and 300-ml water)
Study: 30008106
Drug: Water (500-ml)
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (500-ml)
Study: 21239636
Drug: Low-dose spironolactone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose spironolactone (∼1 mg·kg(‐1)·day(‐1))
Study: 21239636
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose spironolactone (∼30 mg·kg(‐1)·day(‐1))
Study: 14688530
Drug: Sirolimus monotherapy
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus monotherapy (n=11)
Study: 14688530
Drug: Calcineurin inhibitors
Normalized name: Calcineurin inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcineurin inhibitors (n=12)
Study: 9315493
Drug: Yohimbine hydrochloride
Normalized name: Yohimbine Hydrochloride
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine hydrochloride (30 mg/day, two 5 mg tablets three times daily for eight weeks)
Study: 7964947
Drug: rIFN‐gamma at
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN‐gamma at a dose of 4 x 10(6) U subcutaneously per day for 6 months
Study: 7964947
Drug: rIFN‐gamma treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN‐gamma treatment
Study: 3301260
Drug: Five bio‐
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five bio‐ or semisynthetic human insulins (specific preparations not detailed) tested at equal dosages.
Study: 20962913
Drug: Protein plus
Normalized name: Nutritional Supplement Oral Tablet [SAMSON PROTEIN PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein plus carbohydrate (PRO) beverage (40 g carbohydrate, 20 g whey protein)
Study: 20962913
Drug: Carbohydrate (CHO)
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO) beverage (60 g)
Study: 9341603
Drug: Flutamide 250
Normalized name: flutamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide 250 mg/d
Study: 6143975
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 2 X 10(6) units IFN‐beta for 10 consecutive days
Study: 6143975
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections for 10 consecutive days
Study: 6143975
Drug: IFN‐beta treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐beta treatment for non-responders after 3 months
Study: 6143975
Drug: IFN‐beta treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐beta treatment
Study: 6143975
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of IFN‐beta
Study: 29059367
Drug: Metabolism-informed care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metabolism-informed care (MIC)
Study: 22227851
Drug: 1,000 mL
Normalized name: container,empty 1,000 mL MISCELL BOTTLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mL of milk
Study: 22227851
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of milk
Study: 19606529
Drug: Clozapine (250-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (250-600 mg/day)
Study: 17891598
Drug: No GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: No GnRH agonist
Study: 14713745
Drug: Various agents
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various agents including dietary supplements, finasteride, and cyclooxygenase-2 inhibitors
Study: 8074071
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg cholecalciferol
Study: 8074071
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg cholecalciferol
Study: 8074071
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg cholecalciferol every 3 months
Study: 21482217
Drug: Amlodipine/valsartan 10/320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan 10/320 mg (intensive)
Study: 21482217
Drug: Amlodipine/valsartan 5/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan 5/160 mg (moderate)
Study: 15715034
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (two 20 min sessions per week for 16 weeks)
Study: 15715034
Drug: Progressive muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive muscle relaxation (self-administered sessions on the same schedule)
Study: 11280830
Drug: Gabexate mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesilate 1 g/day continuous infusion up to postoperative day 4
Study: 11280830
Drug: Gabexate mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesilate 1 g/day continuous infusion plus octreotide 0.1 mg every 8 hours for 5 days
Study: 10322862
Drug: Tongxinluo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongxinluo capsule (TXLC), 4 capsules, three times daily
Study: 10322862
Drug: Shuxin oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuxin oral liquor (SXOL), 20 ml, two times daily
Study: 8233513
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (isometric strengthening exercises) for 8 weeks followed by 8 weeks of VR
Study: 25479285
Drug: Text messaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text messaging (daily for 2 weeks, alternate days for 2 weeks, weekly thereafter for 22 weeks)
Study: 22715822
Drug: 3% thyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% thyme essential oil antifungal cream
Study: 22715822
Drug: 10% chamomile
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% chamomile extract cream
Study: 12169173
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy (SIT) with standardized Dermatophagoides pteronyssinus extract for 3 years
Study: 6153835
Drug: Corticosteroid ointments
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid ointments (20 tested)
Study: 6153835
Drug: Corticosteroid creams
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid creams (19 tested)
Study: 6153835
Drug: Hydrocortisone preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone preparations (tested with occlusion)
Study: 6153835
Drug: Other corticosteroid
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other corticosteroid preparations (tested with and without occlusion)
Study: 30700068
Drug: Exercise and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise and Manipulation Therapy (EMT)
Study: 24913818
Drug: Broccoli sprout
Normalized name: BROCCOLI SPROUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli sprout beverage providing daily doses of 600 μmol glucoraphanin and 40 μmol sulforaphane
Study: 14760893
Drug: Nelfinavir/nevirapine (1250/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir/nevirapine (1250/200 mg twice daily)
Study: 14760893
Drug: Ritonavir/saquinavir (400/400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir/saquinavir (400/400 mg twice daily)
Study: 2060563
Drug: lormetazepam 0.5
Normalized name: lormetazepam 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lormetazepam 0.5 mg
Study: 30648524
Drug: Combined glucosamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined glucosamine hydrochloride plus chondroitin sulfate (GH+CS) 1500 mg + 1200 mg daily for 6 months
Study: 30576794
Drug: Tanezumab treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab treatment with NSAIDs <90 days (limited NSAID users)
Study: 30576794
Drug: Tanezumab treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab treatment with NSAIDs ≥90 days (chronic NSAID users)
Study: 26600646
Drug: Conventional Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Oral Examination (COE)
Study: 22250063
Drug: Flavonoid-enriched chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavonoid-enriched chocolate (27 g/day, containing 850 mg flavan-3-ols and 100 mg isoflavones)
Study: 10212711
Drug: PCEA (parturient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA (parturient-controlled epidural analgesia) - bolus 5 ml, lockout 15 minutes
Study: 10212711
Drug: CIEA (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIEA (continuous infusion epidural analgesia) - 8 ml/h
Study: 7832129
Drug: Tissue plasminogen
Normalized name: Tissue plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tissue plasminogen activator, anistreplase, or both (exact dosage and duration not specified)
Study: 15190231
Drug: Levodopa (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (single dose)
Study: 2078983
Drug: Haloperidol (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (single dose)
Study: 31951261
Drug: eGFR ≤60
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR ≤60 mL/min/1.73 m2
Study: 31951261
Drug: eGFR =
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR = 45 mL/min/1.73 m2
Study: 31951261
Drug: eGFR <75
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR <75 mL/min/1.73 m2
Study: 31951261
Drug: eGFR ≥75
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR ≥75 mL/min/1.73 m2
Study: 30663038
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal oxygen (30-70 l.min-1)
Study: 30663038
Drug: Standard flow-rate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard flow-rate facemask (15 l.min-1)
Study: 23910386
Drug: Nano-hydroxyapatite-coated mini-implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nano-hydroxyapatite-coated mini-implants
Study: 23910386
Drug: Commercially pure
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially pure titanium mini-implants
Study: 23910386
Drug: Both implant
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both implant surfaces (nano-hydroxyapatite-coated and cp titanium)
Study: 23362969
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg early induction regimen (weeks 0, 1, 2, 4)
Study: 23362969
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg monthly induction regimen (weeks 0, 4, 8)
Study: 23362969
Drug: Fixed-interval secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fixed-interval secukinumab (150 mg at weeks 12 and 24)
Study: 23362969
Drug: Start-of-relapse secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Start-of-relapse secukinumab (150 mg at visits at which a start of relapse was observed)
Study: 21143704
Drug: Gabapentin (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (starting dose 300 mg once daily to a target of 900 mg daily)
Study: 14972420
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) at standard dose (600mg orally twice daily; SD Group; n=110)
Study: 14972420
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) at double dose (1200mg orally twice daily; DD Group; n=114)
Study: 14972420
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) at standard dose (SD Group)
Study: 14972420
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) at double dose (DD Group)
Study: 11856901
Drug: Hypericum (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum (900 mg)
Study: 11856901
Drug: Hypericum (1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum (1800 mg)
Study: 29569389
Drug: SeR-Se-Ly (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SeR-Se-Ly (1 tablet daily for 6 months)
Study: 29569389
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg (1 tablet daily for 6 months)
Study: 24273971
Drug: Danzhi Xiaoyao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danzhi Xiaoyao Pill (DXP) in addition to Metformin and Diane-35
Study: 24273971
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and Diane-35 (Control Group B)
Study: 16530767
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 100 mg/day on days 1-5 of the menstrual cycle (group 1)
Study: 16530767
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 100 mg/day on days 5-9 of the menstrual cycle (group 2)
Study: 7652983
Drug: Local anaesthesia
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthesia with 20 ml of 1% lidocaine
Study: 7652983
Drug: Intravenous anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anaesthesia with pethidine/diazepam
Study: 31247980
Drug: Conventional cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cocoa (CC) 15 g in 200 mL of semi-skimmed milk containing 19.80 mg of flavanols
Study: 31247980
Drug: Flavanol-rich cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavanol-rich cocoa (CC-PP) 25 g in 200 mL of semi-skimmed milk containing 68.25 mg of flavanols
Study: 21873708
Drug: Warfarin (dose-adjusted,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (dose-adjusted, target INR 2.0-3.0)
Study: 20329617
Drug: L-dopa and
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa and ephedrine, orally 1 hour before sexual intercourse for 45 days.
Study: 20329617
Drug: L-dopa and
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa and ephedrine
Study: 7918132
Drug: Isradipine 10
Normalized name: isradipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 10 mg bid
Study: 2830189
Drug: Enalapril, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril, 20 mg daily for 6 weeks
Study: 2830189
Drug: Diltiazem, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem, 120 mg daily for 6 weeks
Study: 2830189
Drug: Nifedipine, 10
Normalized name: Nifedipine, 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, 10 mg p.o. during washout phase
Study: 2830189
Drug: Enalaprilat, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat, 5 mg i.v. during washout phase
Study: 30963177
Drug: Nutrition (child
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition (child nutrition counseling plus lipid-based nutrient supplements)
Study: 26421634
Drug: Active placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo treatment
Study: 26421634
Drug: Inactive placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive placebo treatment
Study: 23491407
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (n = 6)
Study: 20153492
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion (0.05 μg/[kg min])
Study: 19187819
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioral treatment (GCBT)
Study: 15251401
Drug: Oral chloramphenicol
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral chloramphenicol (500 mg every six hours for five days)
Study: 7660719
Drug: Pill-combined and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill-combined and GnRH
Study: 28556962
Drug: 12-h IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-h IV retosiban followed by a single dose of oral placebo (R-P)
Study: 28556962
Drug: 12-h IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-h IV placebo followed by single-dose oral retosiban (P-R)
Study: 25074756
Drug: Topical brimonidine
Normalized name: brimonidine Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical brimonidine tartrate (BT) 0.5% gel, applied once daily for 4 weeks
Study: 25074756
Drug: Vehicle gel,
Normalized name: vehicle gel, anacaulase-bcdb TOPICAL GEL (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle gel, applied once daily for 4 weeks
Study: 17919545
Drug: Garenoxacin 400
Normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Garenoxacin 400 mg QD for 5 days
Study: 17919545
Drug: Garenoxacin 400
Normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Garenoxacin 400 mg QD for 10 days
Study: 17919545
Drug: Garenoxacin 400
Normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Garenoxacin 400 mg QD for 5 or 10 days
Study: 15688694
Drug: Kangfu Xiaozheng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangfu Xiaozheng Tablet
Study: 15688694
Drug: Guizhi Fuling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guizhi Fuling Pill
Study: 11160062
Drug: Ketoprofen (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (300 mg)
Study: 2643965
Drug: Analgesics and
Normalized name: Analgesics and anesthetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics and a standard circumferential rib belt (Zimmer Universal Rib Belt)
Study: 2643965
Drug: Oral analgesics
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral analgesics alone
Study: 29753538
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant (OAC) indication
Study: 23089925
Drug: Statins treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins treatment for 2 weeks
Study: 20166405
Drug: Combination (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (one session plus HB)